Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies

References

• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
   PubMed Web of Science ®Google Scholar
• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961–967.e965.
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–658.
   PubMed Web of Science ®Google Scholar
• Schaefer CP, Cappelleri JC, Cheng R, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol. 2015;73(4):585–593.e583.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Pelletier C, Ung B, et al. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics. J Comp Eff Res. 2020;9(11):767–779.
   PubMed Web of Science ®Google Scholar
• Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28(6):390–403.
   PubMed Web of Science ®Google Scholar
• Otezla [package insert]. Thousand Oaks, CA: Amgen Inc.; 2021.
   Google Scholar
• Karczewski J, Poniedziałek B, Rzymski P, et al. Factors affecting response to biologic treatment in psoriasis. Dermatol Ther. 2014;27(6):323–330.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504–513.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Navaratnam P, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201–209.
   PubMedGoogle Scholar
• Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057–1065.e1054.
   PubMed Web of Science ®Google Scholar
• Murage MJ, Anderson A, Casso D, et al. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. J Dermatolog Treat. 2019;30(2):141–149.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Pelletier C, Ung B, et al. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis. Curr Med Res Opin. 2020;36(1):169–176.
   PubMed Web of Science ®Google Scholar
• Foster SA, Zhu B, Guo J, et al. Patient characteristics, health care resource utilization, and costs associated with treatment-regimen failure with biologics in the treatment of psoriasis. J Manag Care Spec Pharm. 2016;22(4):396–405.
   PubMedGoogle Scholar
• Feldman SR, Tian H, Wang X, et al. Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large U.S. claims database. J Manag Care Spec Pharm. 2018;25:479–488.
   PubMed Web of Science ®Google Scholar
• Guerriero F, Orlando V, Monetti VM, et al. Biological therapy utilization, switching, and cost among patients with psoriasis: retrospective analysis of administrative databases in Southern Italy. Clinicoecon Outcomes Res. 2017;9:741–748.
   PubMed Web of Science ®Google Scholar
• Kaplan DL, Ung BL, Pelletier C, et al. Switch rates and total cost of care associated with apremilast and biologic therapies in biologic-naive patients with plaque psoriasis. Clinicoecon Outcomes Res. 2020;12:369–377.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Pelletier C, Ung B, et al. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. J Med Econ. 2019;22(4):365–371.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Gordon KB, Menter MA, et al. The evolving landscape of psoriasis treatment. Semin Cutan Med Surg. 2018;37(2s):S39–s43.
   PubMedGoogle Scholar
• Higa S, Devine B, Patel V, et al. Psoriasis treatment patterns: a retrospective claims study. Curr Med Res Opin. 2019;35(10):1727–1733.
   PubMed Web of Science ®Google Scholar